Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
Top Cited Papers
Open Access
- 11 January 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1079515
Abstract
Epstein–Barr virus (EBV) was the first tumor virus in humans. Nasopharyngeal carcinoma (NPC) accounts for approximately 60% of the 200,000 new tumor cases caused by EBV infection worldwide each year. NPC has an insidious onset and is highly malignant, with more than 70% of patients having intermediate to advanced disease at the time of initial diagnosis, and is strongly implicated in epithelial cancers as well as malignant lymphoid and natural killer/T cell lymphomas. Over 90% of patients with confirmed undifferentiated NPC are infected with EBV. In recent decades, much progress has been made in understanding the molecular mechanisms of NPC and developing therapeutic approaches. Radiotherapy and chemotherapy are the main treatment options for NPC; however, they have a limited efficacy in patients with locally advanced or distant metastatic tumors. Tumor immunotherapy, including vaccination, adoptive cell therapy, and immune checkpoint blockade, represents a promising therapeutic approach for NPC. Significant breakthroughs have recently been made in the application of immunotherapy for patients with recurrent or metastatic NPC (RM-NPC), indicating a broad prospect for NPC immunotherapy. Here, we review important research findings regarding immunotherapy for NPC patients and provide insights for future research.Keywords
This publication has 166 references indexed in Scilit:
- Emerging treatment options for nasopharyngeal carcinomaDrug Design, Development and Therapy, 2013
- A Virus-Like Particle-Based Epstein-Barr Virus VaccineJournal of Virology, 2011
- EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLLPLOS ONE, 2011
- A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinomaAnnals of Oncology, 2011
- Mapping regions of Epstein–Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gLVirology, 2011
- Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal CarcinomaJournal of Immunotherapy, 2010
- Acquisition of Polyfunctionality by Epstein-Barr Virus-Specific CD8 + T Cells Correlates with Increased Resistance to Galectin-1-Mediated SuppressionJournal of Virology, 2009
- Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patientsBlood, 2009
- Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious MononucleosisJournal of Virology, 2008
- Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)Blood, 2006